PhotoSonix Medical is a biotechnology startup founded in 2014. The company is focused on developing a novel energy-based therapy known as CLENSβ’ (Coincident Light Energy and Non-focused ultraSound), which synergistically combines light and ultrasound energy to address human bacterial biofilms, initially targeting acne and dermal infections. The company has garnered initial data that is showing promising results, creating a buzz in the industry. Currently, PhotoSonix Medical is in the process of raising capital, with its last investment being a grant investment received on 31 January 2017 from Ben Franklin Technology Partners. This innovative approach to medical treatment presents an intriguing opportunity for investors within the health care and medical devices industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | Unknown | 1 |
|
31 Jan 2017 |
| Debt Financing | $1.67M | 2 |
|
13 May 2016 |
| Seed Round | $100.00K | 1 |
|
20 Aug 2014 |
No recent news or press coverage available for PhotoSonix Medical.
We care about your data, and we'd love to use cookies make your experience better.
